Syed Rahman, MD
Hospital ResidentCards
About
Research
Publications
2025
Implementing HoLEP without fellowship training: A stepwise learning curve from a single surgeon’s first 200 cases
Smani S, Sohoni N, Lacy G, Kong V, Rahman S, Hayden C, Gardezi M, Jalfon M, Kellner D. Implementing HoLEP without fellowship training: A stepwise learning curve from a single surgeon’s first 200 cases. Canadian Urological Association Journal 2025, 20 PMID: 41406344, DOI: 10.5489/cuaj.9351.Peer-Reviewed Original ResearchPartial Cystectomy for Muscle-Invasive Bladder Cancer
Palencia P, Sivanesan N, Rahman S, Ghali F, Hesse D, Colberg J, Sridhar A, Kelly J, Lee B, Kamat A, Tan W. Partial Cystectomy for Muscle-Invasive Bladder Cancer. Cancers 2025, 17: 2562. PMID: 40805257, PMCID: PMC12346575, DOI: 10.3390/cancers17152562.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerPartial cystectomyBladder cancerBladder-sparing optionsBlue light cystoscopyProstatic urethral biopsyNeoadjuvant systemic therapyCancer-specific survivalRecurrence-free survivalCarcinoma in situLength of stayUrethral biopsyCT urogramUrinary cytologyMapping biopsyNegative marginsRadiation therapyBladder tumorsRadical cystectomySystemic therapyDefinitive pathologyMIBC patientsMultifocal diseaseOverall survivalUrachal adenocarcinomaEvaluating the Therapeutic Role of Lymph Node Dissection in Variant Subtype Bladder Cancer
Rahman S, Martin D, Keervani K, James S, Humphrey P, Hesse D, Tan W, Patel S, Wright J, Ghali F. Evaluating the Therapeutic Role of Lymph Node Dissection in Variant Subtype Bladder Cancer. Cancers 2025, 17: 2536. PMID: 40805235, PMCID: PMC12346734, DOI: 10.3390/cancers17152536.Peer-Reviewed Original ResearchLymph node dissectionRadical cystectomyBladder cancerNodal dissectionNode dissectionTherapeutic benefitUrothelial carcinomaTherapeutic benefit of lymph node dissectionBenefit of lymph node dissectionImpact of lymph node dissectionTherapeutic roleCox proportional hazards analysisPathological nodal statusNational Cancer DatabaseRisk-adapted approachKaplan-Meier analysisTime of surgeryCox proportional hazards regressionProportional hazards analysisProportional hazards regressionInternational ClassificationNeuroendocrine subtypeLN dissectionMedian OSNodal statusCan Anatomical Measurements on Preoperative Pelvic Magnetic Resonance Imaging Predict Postoperative Urinary Incontinence after Holmium Laser Enucleation of the Prostate?
Smani S, Khan A, Choksi A, Press B, Rahman S, Hayden C, Gardezi M, Jalfon M, Lee J, Sprenkle P, Kellner D. Can Anatomical Measurements on Preoperative Pelvic Magnetic Resonance Imaging Predict Postoperative Urinary Incontinence after Holmium Laser Enucleation of the Prostate? Journal Of Endourology 2025, 39: 731-737. PMID: 40470526, DOI: 10.1089/end.2025.0006.Peer-Reviewed Original ResearchIntravesical prostatic protrusion lengthMembranous urethral lengthLevator ani thicknessPostoperative urinary incontinenceHolmium laser enucleationUrinary incontinenceReceiver Operating CharacteristicLaser enucleationPredictors of urinary incontinenceAnatomical measurementsPreoperative anatomic measurementsPad per dayProstate-specific antigenPreoperative MRI imagesReceiver operating characteristic analysisImprove risk stratificationBody mass indexPerioperative management strategiesOdds of incontinenceLogistic regression analysisNo significant associationModerate discriminatory powerUrethral angleIncontinence riskPreoperative incontinenceEVALUATING CLINICAL OUTCOMES AND THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN PLASMACYTOID UROTHELIAL CARCINOMA: INSIGHTS FROM A COMBINED NATIONAL AND INSTITUTIONAL SERIES
Rahman S, Kong V, Jalfon M, Hesse D, Kim J, Wright J, Adeniran A, Humphrey P, Martin D, Ghali F. EVALUATING CLINICAL OUTCOMES AND THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN PLASMACYTOID UROTHELIAL CARCINOMA: INSIGHTS FROM A COMBINED NATIONAL AND INSTITUTIONAL SERIES. Urologic Oncology Seminars And Original Investigations 2025, 43: 43. DOI: 10.1016/j.urolonc.2024.12.109.Peer-Reviewed Original ResearchPlasmacytoid urothelial carcinomaNational Cancer DatabaseMedian overall survivalNeoadjuvant chemotherapyUrothelial carcinomaOverall survivalImpact of neoadjuvant chemotherapyResponse to current therapiesCharacterize treatment patternsPrimary treatment typeCox proportional hazards analysisSite of metastasisEvaluate clinical outcomesProportional hazards analysisBorderline statistical significancePT0 rateOS benefitHistological subtypesCancer DatabaseClinical stageClinical outcomesTreatment patternsCurrent therapiesInstitutional experiencePrimary outcomeAdvancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer
Smani S, DuBois J, Zhao K, Sutherland R, Rahman S, Humphrey P, Hesse D, Tan W, Martin D, Lokeshwar S, Ghali F. Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer. Current Oncology Reports 2025, 27: 236-246. PMID: 39976835, DOI: 10.1007/s11912-025-01645-7.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerInvasive bladder cancerBladder cancerRisk stratificationBCG-unresponsive NMIBCEarly radical cystectomyTERT promoter mutationsHigh-risk casesLong-term outcomesNadofaragene firadenovecIntravesical therapyTransurethral resectionRadical cystectomyTreatment paradigmStratified careReduce overtreatmentProgression riskIntegration of biomarkersPromoter mutationsClinical trialsTherapeutic strategiesReviewThis reviewPersonalized treatmentAdverse effectsClinical careModeling survival outcomes of KEYNOTE-564 with standard of care control arm treatment: A simulation study.
Ghali F, Rahman S, James S. Modeling survival outcomes of KEYNOTE-564 with standard of care control arm treatment: A simulation study. Journal Of Clinical Oncology 2025, 43: 517-517. DOI: 10.1200/jco.2025.43.5_suppl.517.Peer-Reviewed Original ResearchStandard of careKEYNOTE-564KEYNOTE-426Renal cell carcinomaCheckpoint inhibitorsUnadjusted hazard ratioOverall survivalControl armHazard ratioPatient-level survival dataFirst-line settingImproved overall survivalProportion of patientsKaplan-Meier plotsMortality riskSurvival parametersControl group patientsOne-year mortality riskCell carcinomaFirst-lineSurvival outcomesControl patientsGroup patientsSurvival curvesArm treatmentRadical prostatectomy is associated with favorable outcomes in patients over 80 years old.
Kim I, Leapman M, Kim M, Rahman S, Sprenkle P, Renzulli J, Brito J, Hyams E, Kim J, Pareek G, Kim I. Radical prostatectomy is associated with favorable outcomes in patients over 80 years old. American Journal Of Clinical And Experimental Urology 2025, 13: 33-42. PMID: 40124572, PMCID: PMC11928824, DOI: 10.62347/nkgs2301.Peer-Reviewed Original ResearchProstate cancer-specific survivalLocalized prostate cancerRadical prostatectomyProstate cancerPatients treated with radical prostatectomyAssociated with higher OSAssociated with favorable outcomesCancer-specific survivalTreated with radiotherapyMedian OSMedian PSAFavorable survivalMedian agePatient ageFavorable outcomeHigher OSRadiotherapySEER-17Cox regressionCompare survivalProstatectomyPatientsSurvivalCancerDiagnosis
2024
Management strategies for radio-recurrent prostate cancer: a comprehensive review
Rahman S, Kim H, Webb L, Diaz G, Leapman M, Sprenkle P, Brito J, Renzulli J, Martin T, Kenney P, Kim I. Management strategies for radio-recurrent prostate cancer: a comprehensive review. Translational Cancer Research 2024, 0: 0-0. PMID: 39697737, PMCID: PMC11651831, DOI: 10.21037/tcr-24-245.Peer-Reviewed Original ResearchDiagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy
Press B, Lokeshwar S, Webb L, Khajir G, Smani S, Olawoyin O, Gardezi M, Rahman S, Leapman M, Sprenkle P. Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 1168-1176. PMID: 39465014, PMCID: PMC11502073, DOI: 10.37349/etat.2024.00269.Peer-Reviewed Original ResearchProstate Health IndexMRI-ultrasound fusion targeted biopsyClinically Significant Prostate CancerFusion targeted biopsyPI-RADS 1Gleason grade groupMagnetic resonance imagingPhi densityPI-RADSProstate specific-antigenProstate biopsyImproved detection of clinically significant prostate cancerDetection of clinically significant prostate cancerPHI testingProstate health index densityElevated prostate-specific antigenMRI-ultrasound fusionProstate Imaging ReportingSignificant prostate cancerProstate-specific antigenSelection of patientsDetection of PCaReceiver operating characteristic curveCombination of magnetic resonance imagingMultivariate logistic regression
News
News
- October 27, 2025
Yale Urology Research
- July 29, 2025
Yale Urology Research [Q2: April-June 2025]
- June 25, 2025
2025 Yale Urology Visiting Professor and Graduation Day
- April 15, 2025
Yale Urology Research [Q1: January-March 2025]
Get In Touch
Contacts
Email